Q: I read in a reply to a question about Intelgenx technologies you indicated that insiders owned less than 2%, insiders own close to 18%. Company seems to have a lot of irons in the fire namely exclusivity with Eli Lily for their Cialis drug partnership with Endo/Par for subaxone, 4drug app to be filed by 2018 in collaboration with Insud pharma, approval for migraine drug in Europe,health canada approval for manufacturing site, Alzheimer's trial Maxim group initiating with a 12month us$3 target. I am heavily invested in the company and would love to hear unbiased thoughts on the company in light of the recent developments. Thanks and look forward to ur reply
Q: Johnson and Johnson is a highly rated company. However they are facing a large number of law suits, mostly related to talcum powder. Although the scientific basis for these lawsuits is extremely weak, I am concerned about the legal system in the USA. Would you recommend I keep holding my JNJ shares or sell and invest in something else in the USA? Diversification is not an issue.
Q: Regarding your comment on GUD this morning, I think Canaccord raised their price estimate from $7.90 to $10.75 which could account for the price bump.
Q: Hi Ryan.I am up $18000. on 3100 shares of SIS..With the way it looks should I sell 1-2 of these shares or should i just hang in there. If I should sell some where would you put the$$. Thanks in advance.. Cliff
Q: Prometic is up 12% today on high volume. It has been such a sleepy hollow stock that it is a bit of a hock to see it moving. Are you aware of any news on this company?
Q: I recently entered into a 2% position in the recent dip when Amazon announced the PillPack acquisition. This dip was shortly after WBA's addition to the DOW. Do companies historically see short to medium term strength after being added to the DOW? The long term trend isn't great on WBA so I am trying to decide whether I should lock in profits and enjoy the successful trade or hold it longer term as an investment. My healthcare allocation is ~5% including WBA.
Looking at COV. Seems like there is a huge difference between Shares Outstanding and Floating shares. Does this mean that there are a lot of shares locked by insiders? When are these scheduled to be able to be traded and is that a concern for the future with the stock up so much? With the large run up lately, do you still feel it is a good buying opportunity or would you wait for a pull back as the chart gives me a bit of a pause.
Q: Mr. Hodson, what is this matter about GUD being reassessed for past activities dating back to 2014. Is this a serious matter ? What is the likely outcome in your opinion ?
Q: Good Morning any thoughts about the news this morning in regards to the CRA tax re-assement? Looks like CRA and QRA are challenging the sale of the voucher back in 2014 and concluded that GUD owes $42MM. Gud plans on appealing this, any thoughts on this issue?
Thanks
Q: Healthcare is approximately 10% of our portfolio. Medical Facilities is the largest investment which we have held for a long time. JNJ and HCP we have added more recently. NVS and AZN we inherited. We want to simplify our portfolio and plan to sell NVS and AZN and add to JNJ. Wonder what your opinion is of DR and HCP specifically and also AZN which I didn't see mentioned in your question section.
Thank you, Marie
Q: The GUD investing thesis is largely based on management including past success with Paladin. Paladin was certainly a well run company and created lots of value for shareholders so credit to management is not misplaced. But, do you think that the ultimate success with Paladin was more a function of incredibly lucky timing to have been taken out during a really crazy pharma cycle? In other words, how much credit goes to management and how much goes to a once in a generation crazy pharma cycle?
Q: I think looking at chart at $ 16.00 SIS is a buy. When do they report next eps. I see ACORN ads on TV . Same product Chair Lift. I believe Acorn is a UK Company. Your thoughts pleas. RAK